

Date	Time	Track	Presentation Title	Speaker
21-Feb	06:00 - 07:00 AM	Pharmacogenomics and Personalized Medicine	Using HDAC Inhibitors to Improve Cancer Immunotherapy	Alejandro Villagra, PhD Assistant Professor of Biochemistry and Molecular Medicine, GW School of Medicine and Health Sciences
21-Feb	07:30 - 08:30 AM	Pharmacogenomics and Personalized Medicine	Keynote Presentation: Evolving Paradigms of Pharmaco- MPE (Molecular Pathological Epidemiology) and Immuno- MPE for Precision Medicine	Shuji Ogino, MD, PhD, MS Chief, Program in MPE Molecular Pathological Epidemiology, Brigham and Women's Hospital, Professor of Pathology and Epidemiology, Harvard Medical School, Dana-Farber Cancer Institute
21-Feb	09:00 - 10:00 AM	Biomarkers in Early Stage Drug Development	Application of a Novel Cell Proliferation Biomarker in Cancer Drug Development: Immunoassay of Thymidine Kinase 1 in In-Vitro and In-Vivo Studies of Hematological and Solid Malignancies	Martin Shaw Business Development, AroCell AB
21-Feb	09:00 - 10:00 AM	GPCR Drug Discovery	New Tools for Understanding Allosteric Signaling in G Protein Coupled Receptors	Matthew Eddy, PhD Postdoctoral Research Fellow, The Scripps Research Institute
21-Feb	09:00 - 10:00 AM	Pharmacogenomics and Personalized Medicine	Transcriptomic Analysis of a Botanical Complex for the Topical Treatment of Atopic Dermatitis	Joe Sherrill, PhD Senior Scientist, Global Biosciences, Bioinformatics Group, The Procter & Gamble Company
21-Feb	10:30 - 11:30 AM	Pharmacogenomics and Personalized Medicine	Panel Discussion: Co-development of Drugs and Companion Diagnostics	Annette Gilchrist, PhD Associate-Professor, Pharmaceutical Sciences, Midwestern University Martin Shaw Business Development, AroCell AB Thomas Webster, PhD Professor and Department Chair, Chemical Engineering, Art Zafiropoulo Chair in Engineering, Affiliated Faculty, Bioengineering, Northeastern University, College of Engineering

21-Feb	10:30 - 11:30 AM	Emerging Trends	The Effects of Epigenetic Therapies on the Tumor and Host Immune System	Katherine Chiappinelli, PhD Assistant Professor of Microbiology, Immunology, & Tropical Medicine at The George Washington University
21-Feb	12:00 - 01:00 PM	GPCR Drug Discovery	Allosteric Modulation of Metabotropic Glutamate Receptors for the Treatment of Neurodevelopmental Disorders	Colleen Niswender, PhD Professor of Pharmacology, Director of Molecular Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery
21-Feb	12:00 - 01:00 PM	Pharmacogenomics and Personalized Medicine	Precision Medicine: Using Genotype to Inform Prescribing	Larisa Cavallari, Pharm. D. Associate Professor & Director, Center for Pharmacogenomics, University of Florida College of Pharmacy
21-Feb	01:30 - 02:30 PM	GPCR Drug Discovery	Can CADD Drive GPCR Drug Design? Rapid Estimation of Relative Binding Affinities Based on Pre-computed Ensembles	Alexander MacKerell, PhD Grollman-Glick Professor of Pharmaceutical Sciences, Director, Computer-Aided Drug Design Center, University of Maryland School of Pharmacy
21-Feb	01:30 - 02:30 PM	Emerging Trends	Liposomes for Drug Delivery and Targeting: Examples of Their Potential from Our Laboratories Research	Sophia Antimisiaris, PhD Professor, University of Patras & Institute of Chemical Engineering FORTH/ICE-HT
22-Feb	06:00 - 07:00 AM	Pharmacogenomics and Personalized Medicine	Developing Personalized Cancer Neoantigen Vaccines	Agnete Fredriksen, MSc, PhD Chief Scientific Officer, Vaccibody AS
22-Feb	06:00 - 07:00 AM	Emerging Trends	Testing for Soluble ST2: Opening New Perspectives for Cardiovascular Diseases	Damien Gruson, PhD Professor, Head of the Department of Clinical Biochemistry, Cliniques Universitaires Saint Luc
22-Feb	07:30 - 08:30 AM	Biomarkers in Early Stage Drug Development	Keynote Presentation: Predictive Biomarkers to Diagnostic Tests - Scientific and Regulatory Consideration in Development of Companion Diagnostic Tests	Janaki Veeraraghavan, PhD Biologist, CDRH/OIR/DMGP, U.S. Food and Drug Administration
22-Feb	09:00 - 10:00 AM	Pharmacogenomics and Personalized Medicine	Clinical Implementation of Pharmacogenomics: Delivering Genomics to the Bedside	Mark Dunnenberger, PharmD Director, Pharmacogenomics at NorthShore University HealthSystem

22-Feb	09:00 - 10:00 AM	Biomarkers in Early Stage Drug Development	Integrated Interrogation of Oncogenic Signaling Pathways, Immunology, and Heterogeneity in Cancer	Michael Davies, MD, PhD Deputy Chairman and Associate Professor in the Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center Joseph M Beechem, PhD Senior Vice President of Research and Development, NanoString Technologies
22-Feb	10:30 - 11:30 AM	GPCR Drug Discovery	Illuminating the Druggable GPCR-ome	Bryan L. Roth, MD, PhD Michael Hooker Distinguished Professor, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy
22-Feb	10:30 - 11:30 AM	Emerging Trends	Protective Effect of a Novel Noncompetitive IL-1 Receptor-Biased Ligand in an Infection - and Inflammation-Induced Preterm Birth as Well as in Fetal Injury and Developmental Outcomes	Sylvain Chemtob, MD, PhD, FRCPC, FAAP, FCAHS Professor of Pediatrics, Ophthalmology, Optometry and Pharmacology, Université de Montréal, Adjunct Professor of Pharmacology, McGill University, Université de Montréal
22-Feb	12:00 - 01:00 PM	Emerging Trends	Commercializing Nanomedicine for Improving Human Health: Not Just Hype, It Is Really Happening!	Thomas Webster, PhD Professor and Department Chair, Chemical Engineering, Art Zafiropoulo Chair in Engineering, Affiliated Faculty, Bioengineering, Northeastern University, College of Engineering
22-Feb	12:00 - 01:00 PM	GPCR Drug Discovery	New Structure Based Drug Design Opportunities for GPCRs and Related Transporters	Sid Topiol, PhD Chief Scientific Officer, 3D-2drug LLC
22-Feb	01:30 - 02:30 PM	GPCR Drug Discovery	Recent Trends in GPCR Drug Discovery: Novel Targets, New Disease Indications, and an Upsurge in Biologics	Annette Gilchrist, PhD Associate-Professor, Pharmaceutical Sciences, Midwestern University